Physician profile
Leigh Perreault
NPI 1669562344
$1,657,613.63
in general payments reported to CMS, 2019-2025
15 companies · $220K in 2025
The $220K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320K · 2020: $206K · 2021: $237K · 2022: $265K · 2023: $184K · 2024: $226K · 2025: $220K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $410K · Consulting Fee: $122K · Travel and Lodging: $82K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $410,286.01 |
| Consulting Fee | $122,013.45 |
| Travel and Lodging | $82,490.82 |
| Food and Beverage | $14,765.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $495,926.78 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $483,498.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260,492.08 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $122,124.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $75,311.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51,584.86 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $45,268.05 | 2019-2020 | |
| Boehringer Ingelheim International Gmbh | $42,730.37 | 2025 | |
| Janssen Pharmaceuticals, INC | $33,970.67 | 2019-2024 | Xarelto |
| Eli Lilly and Company | $31,483.14 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk As | $11,609.96 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $3,540.00 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $28.48 | 2019 | |
| Amryt Pharma Holdings LTD | $27.01 | 2023 | Myalept |
| Mannkind Corporation | $17.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Perreault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.